Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genistein for Heart Failure Inflammation
NCT06501768Phase 2Recruiting
- Sponsor
- University Medical Centre Ljubljana
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of genistein in heart failure (HF), sponsored by University Medical Centre Ljubljana. Primary endpoint: HF inflammatory and cardiometabolic markers at 18 weeks. Started Jul 2024; status: recruiting.
02
Drugs
genistein
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06501768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06501768.